Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 15;103(6):959–971. doi: 10.3324/haematol.2017.183202

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 2. — NSG-S mice enhanced the engraftment of human patients’ acute myeloid leukemia (AML) samples more than NSG mice (non-NSG engrafted patients’ samples were used). (A) Levels of hCD45⁺CD33⁺ leukemia blasts in bone marrow (BM), spleen (SPL) and peripheral blood (PB) of NSG or NSG-S mice (n=14) injected with the same number of AML cells. (B) Individual mouse BM and SPL leukemia burdens of 11 out of the 14 mice from (A) are shown. (C) Receptor densities (CD116, CD117 and CD123) on AML cells of the 7 non-NSG-S engrafters and 14 NSG-S engrafters were assessed as number of receptors per cell. (D) Establishment of 8 inv(16) AML patient-derived xenotransplant models in NSG-S mice. (E) The chromosomal abnormalities for inv(16) were confirmed in the BM of engrafted NSG-S mice by fluorescent in situ hybridization (left panels) and breakpoint reverse transcriptase polymerase chain reaction (right panel).